Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 4/20 | 0.45 |
| ▸ | BRAF | P15056 | 4/20 | 0.45 |
| ▸ | CSF1R | P07333 | 3/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.45 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13434910 | 0.90 | AURKA (0.49) | MAPTMAPK1NOD2RAF1BRAF | |
| SCHEMBL13434856 | 0.78 | FADS1 (0.59) | AURKANTRK1CSNK2A1 | |
| SCHEMBL4737834 | 0.76 | FADS1 (0.60) | MAPTMAPK1RAF1BRAFCSF1R | |
| SCHEMBL13434869 | 0.76 | F9 (0.52) | MAPK1RAF1BRAFCSF1RDDR1 | |
| SCHEMBL29116330 | 0.75 | MAPT (0.51) | MAPTMAPK1LPAR1LPAR2MAPK14 | |
| SCHEMBL9930746 | 0.74 | DHODH (0.49) | MAPK1AURKARPS6KB1MAPK14MEN1 | |
| SCHEMBL4922291 | 0.72 | SMN1; SMN2 (0.44) | BRAFAURKARPS6KB1MEN1NPC1 | |
| SCHEMBL29116561 | 0.72 | EGFR (0.60) | — | |
| SCHEMBL7892355 | 0.71 | KDR (0.52) | MAPTMAPK1LPAR1LPAR2NPC1 | |
| SCHEMBL13402694 | 0.70 | EGFR (0.62) | AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633201-B2 | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-8633201-B2 | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-03-04 | — | — | US | disclosed |
| WO-2007115822-A1 | THIENOPYRIMIDINES HAVING MNKL /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | CMPK1, DTYMK, NEK9 | MAPT 1829/4885MAPK1 483/4885NOD2 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.